


Financial Highlights / Non-Financial Highlights


SHIONOGI has adopted International Financial Reporting Standards (IFRS) from fiscal 2019. The financial figures for fiscal 2018 are shown according to both Japanese Generally Accepted Accounting Principles (JGAAP) and IFRS.

■ Revenue




Revenue was ¥335.1 billion, a 12.8 percent increase year on year. Domestic revenue of prescription drugs were ¥89.1 billion, a decrease of 5.9 percent year on year, as a result of the launch of a generic version of *Cymbalta*. On the other hand, revenue from overseas subsidiary sales and exports was ¥34.4 billion, a 39.5 percent increase year on year, due to the growth in sales of cefiderocol in the U.S. and Europe. Royalty income was ¥181.3 billion, a 25.3 percent increase year on year, due to the growth in royalty income from the HIV franchise.

■ R&D expenses




■ Operating profit/Operating profit margin




Operating profit was ¥110.3 billion, a 6.1 percent decrease year on year, as research and development expenses increased due to aggressive investment in projects related to COVID-19. Core operating profit, which excludes non-recurring items, was ¥110.6 billion, an increase of 17.7 percent year on year.

■ Royalty income




Royalty income was ¥181.3 billion, a 25.3% increase year on year, as sales of the HIV franchise out-licensed to UK-based ViV Healthcare Limited. grew, and royalty income accompanying the settlement of the patent infringement litigation against U.S.-based Gilead Sciences, Inc. was recorded.

■ Dividends per share/DOE



Dividends per share were ¥115, up ¥7 from the previous year, making this our tenth consecutive year of dividend growth. DOE was 3.8%.

■ ROE



ROE was 12.5%. The introduction of IFRS resulted in a lower ROE, due to the impact of an increase in equity items (equity attributable to owners of the parent).

Financial Highlights / Non-Financial Highlights

Code of Conduct signature rate (FY2021)

100%


* Shionogi & Co., Ltd. and its domestic group companies

Education and training expenses per person (FY2021)

¥48 thousand

*(Education and training expenses + amount of self-investment support)/number of employees (Domestic consolidation)

Acquisition rate of childcare leave




○ Female ○ Male

FY2022 target (Male)

Acquisition rate of childcare leave/days off for childcare purposes of **50%** or more for male employees

GHG emissions (Scope 1 and 2)



FY2030 target*


FY2050 target

down **46.2%** (FY2019 benchmark)

Zero

* This includes emissions by UMN Pharma Inc. and Nagase Medicals Co., Ltd., (currently Shionogi Pharma Co., Ltd., Itami Plant) since 2019, the reference year, because that is the boundary for fiscal 2030 targets (SBT).

Ratio of female managers



○ Nonconsolidated ○ Domestic consolidation

FY2022 target (domestic consolidation)

Rate of female employees occupying management positions: at least **15%**

External evaluations

	FY2019	FY2020	FY2021
CDP	Climate change: A- Water Security: A	Climate change: A- Water Security: A SER*: Leaderboard	Climate change: A- Water Security: A- SER: Leaderboard
FTSE	Not selected/2.9	Selected/3.4	Selected/3.7
MSCI	AA	AA	AA
DJSI	No response/19 points	Response/45 points	Response/53 points
S&P/JPX Carbon Efficient Index	Third decile	Fourth decile	Fifth decile
Toyo Keizai CSR Ranking	63rd of 1,593 companies	34th of 1,614 companies	53rd of 1,631 companies
SOMPO Sustainability Index	Selected	Selected	Selected
Survey on Health and Productivity Management	White 500	White 500	Certified Health & Productivity Management Outstanding Organizations

* SER: Supplier Engagement Rating

At a glance

■ Core operating profit margin (FY2021)

33.0%

■ ROE (FY2021)

12.5%

■ Internally-discovered pipeline ratio (as of Mar. 2022)

73%

■ COVID-19 pipeline (as of August 1, 2022)

Area	Pipeline	Indication	Status
Infectious disease	S-217622 (ensitrelvir)	COVID-19 treatment	Japan: Application, phase2/3 clinical trials in progress Global: Phase 3 clinical trials in progress
	S-268019	COVID-19 prevention (muscular injection)	Japan/global: Phase 3 clinical trials in progress
	S-555739 (asapirant)	Control of the aggravation of COVID-19	US: Phase 2
	S-875670	COVID-19 nasal vaccine	Nonclinical studies in progress

■ Main pipeline (as of August 1, 2022)

Area	Pipeline	Indication	Status
Infectious disease	S-872600	Influenza nasal vaccine	Nonclinical studies in progress
	S-540956	① Infectious disease ② Cancer	Preparing for Phase 1 clinical trials
Neuropsychiatric disease	S-600918 (sivopixant)	Refractory/unexplained chronic cough	Preparing for Phase 3 clinical trials
	S-812217 (zuranolone)	Depression	Preparing for Phase 3 clinical trials
	BPN14770 (zatolmilast)	Fragile X syndrome	Phase 2b/3 clinical trials in progress
New growth areas	S-531011	Solid tumors	Phase 1b/2 clinical trials in progress
	S-005151 (redasemtide)	① Epidermolysis bullosa ② Acute ischemic stroke ③ Knee osteoarthritis ④ Chronic liver disease ⑤ Cardiomyopathy	① Started additional clinical trials ② Preparing for Phase 3 clinical trials ③ ④ Investigator-initiated clinical trials (Phase 2 clinical trials) in Progress ⑤ Preparing for investigator-initiated clinical trials

■ Proportion of R&D expenses for the infectious disease area (FY2021)



* Labor costs and indirect spending not included.

11-Year Financial Summary

Third Medium-Term Business Plan

SONG for the Real Growth
Progress toward global growth

Shionogi Growth Strategy 2020

Grow as a drug discovery-based pharmaceutical company
(FY2014-September FY2016)

Grow sustainably as a drug
(October FY2016-FY2019)

JGAAP	2012	2013	2014	2015	2016	2017
For the years ended March 31:						
Net sales	¥ 267,275	¥ 282,903	¥ 289,717	¥ 273,991	¥ 309,973	¥ 338,890
Cost of sales	77,753	78,574	77,993	82,189	74,758	77,777
Selling, general and administrative expenses	142,518	144,764	149,848	141,436	143,808	152,934
Operating income	47,003	59,565	61,875	50,365	91,406	108,178
Ordinary income	46,093	58,922	62,225	77,880	100,869	123,031
Profit before income taxes	41,494	58,306	63,188	82,051	97,452	122,695
Profit attributable to owners of parent	27,101	66,727	40,618	44,060	66,687	83,879
Net cash provided by operating activities	54,724	59,276	79,496	45,604	102,290	111,903
Net cash used in investing activities	(38,290)	(19,959)	(20,040)	(31,696)	(32,894)	(31,643)
Net cash used in financing activities	(27,749)	(37,687)	(53,798)	(46,211)	(18,525)	(57,411)
Research and development expenses	53,599	53,021	53,605	48,870	49,787	59,907
Capital investments	13,233	11,447	8,962	8,163	9,943	9,659
Depreciation and amortization	16,282	11,912	12,912	12,672	12,578	13,362
As of March 31:						
Property, plant and equipment, net	¥ 74,282	¥ 78,473	¥ 78,976	¥ 77,022	¥ 78,673	¥ 78,788
Intangible assets	106,694	70,464	72,824	80,328	71,626	91,125
Total assets	522,161	574,882	580,566	595,067	631,599	661,499
Total long-term liabilities	92,899	53,041	33,721	48,427	45,739	44,692
Total net assets	347,198	423,633	467,836	478,883	513,877	526,211
Per share amounts:						
Profit attributable to owners of parent	¥ 80.93	¥ 199.25	¥ 121.29	¥ 132.67	¥ 204.83	¥ 259.88
Net assets	1,027.83	1,254.44	1,385.11	1,456.70	1,564.73	1,638.46
Dividend	40	42	46	52	62	72
Other:						
Equity ratio	65.9	73.1	79.9	79.7	80.7	79.0
Return on equity [ROE]	8.1	17.5	9.2	9.4	13.6	16.3
Payout ratio	49.4	21.1	37.9	39.2	30.3	27.7

Notes: 1. From the fiscal year ended March 31, 2015, the Company has adopted a new accounting standard for research and development expenses (business research expenses). This change has been reflected in figures for the fiscal year ended March 31, 2014.

2. In the fiscal year ended March 31, 2019, the Company changed the presentation method for tax effect accounting. The change has been reflected in figures for the fiscal year ended March 31, 2015, and subsequent periods.

3. International Financial Reporting Standards (IFRS): Accounting standards defined by the non-government organization International Accounting Standards Board (IASB) headquartered in London.

4. IFRS adopted from the fiscal year ended March 31, 2020.

2018	2019		2019	2020	2021	2022
	(Millions of yen)	International Financial Reporting Standards (IFRS)				
¥ 344,667	¥ 363,721	For the years ended March 31:				(Millions of yen)
73,911	54,880	Revenue	¥ 367,960	¥ 333,371	¥ 297,177	¥ 335,138
155,537	170,303	Cost of sales	(55,591)	(56,782)	(52,523)	(55,415)
115,219	138,537	Selling, general and administrative expenses	(87,668)	(95,094)	(91,902)	(91,771)
138,692	166,575	Research and development expenses	(52,058)	(47,949)	(54,249)	(72,996)
137,378	170,343	Operating profit	145,081	130,628	117,438	110,312
108,866	132,759	—	—	—	—	—
129,790	145,684	Profit before tax	174,043	158,516	143,018	126,268
(51,238)	(36,349)	Profit attributable to owners of parent	137,191	122,193	111,858	114,185
(53,893)	(87,011)	Net cash provided by operating activities	165,000	131,940	109,039	102,068
59,945	68,325	Net cash used in investing activities	(56,256)	(29,144)	(5,261)	(96,204)
5,678	7,900	Net cash used in financing activities	(89,912)	(88,174)	(43,891)	(36,615)
15,972	16,479	Capital investments	7,900	9,954	27,371	27,274
		Depreciation and amortization	14,431	14,115	14,779	16,351
	(Millions of yen)	As of March 31:				(Millions of yen)
¥ 75,956	¥ 74,653	Property, plant and equipment, net	¥ 70,986	¥ 71,350	¥ 90,883	¥ 108,893
75,060	54,769	Intangible assets	47,804	51,705	76,558	81,223
711,463	778,741	Total assets	938,540	873,695	998,992	1,150,601
34,056	17,203	Total equity	813,087	765,203	864,550	993,285
604,840	672,429	Non-current liabilities	29,303	27,372	34,261	32,920
	(Yen)	Per share amounts:				(Yen)
¥ 342.71	¥ 424.31	Basic earnings per share	¥ 438.47	¥ 395.71	¥ 365.03	¥ 378.75
1,911.36	2,144.33	Equity attributable to owners of parent per share	2,598.16	2,518.74	2,806.67	3,236.21
82	94	Dividend	94	103	108	115
	(%)	Other:				(%)
84.5	85.7	Ratio of equity attributable to owners of parent	86.2	87.6	84.7	84.8
19.4	20.9	Return on equity attributable to owners of parent (ROE)	17.8	15.5	13.9	12.5
23.9	22.2	Payout ratio	21.4	26.0	29.6	30.4

Consolidated Financial Statements

Consolidated statement of financial position

(Millions of yen)

	As of March 31, 2021	As of March 31, 2022
Assets		
Non-current assets		
Property, plant and equipment	¥ 90,883	¥ 108,893
Goodwill	9,357	9,638
Intangible assets	76,558	81,223
Right-of-use assets	4,827	3,524
Investment property	26,759	26,672
Other financial assets	217,437	242,479
Deferred tax assets	11,729	12,907
Other non-current assets	5,200	6,055
Total non-current assets	442,754	491,396
Current assets		
Inventories	38,003	45,892
Trade receivables	78,047	122,965
Other financial assets	142,151	210,757
Income taxes receivable	164	51
Other current assets	21,697	25,117
Cash and cash equivalents	276,173	254,420
Total current assets	556,238	659,205
Total assets	998,992	1,150,601

(Millions of yen)

	As of March 31, 2021	As of March 31, 2022
Equity and liabilities		
Equity		
Share capital	¥ 21,279	¥ 21,279
Capital surplus	13,733	14,455
Treasury shares	(57,989)	(57,857)
Retained earnings	752,248	832,958
Other components of equity	116,836	164,824
Equity attributable to owners of parent	846,108	975,661
Non-controlling interests	18,442	17,624
Total equity	864,550	993,285
Liabilities		
Non-current liabilities		
Lease liabilities	4,608	3,729
Other financial liabilities	5,242	5,616
Retirement benefit liability	16,318	15,412
Deferred tax liabilities	7,749	7,807
Other non-current liabilities	341	354
Total non-current liabilities	34,261	32,920
Current liabilities		
Lease liabilities	3,379	2,945
Trade payables	9,902	16,372
Other financial liabilities	21,383	22,027
Income taxes payable	28,033	17,973
Other current liabilities	37,481	65,078
Total current liabilities	100,180	124,396
Total liabilities	134,442	157,316
Total equity and liabilities	998,992	1,150,601

Consolidated Financial Statements

Consolidated statement of profit or loss

(Millions of yen)

	Year ended March 31, 2021	Year ended March 31, 2022
Revenue	¥ 297,177	¥ 335,138
Cost of sales	(52,523)	(55,415)
Gross profit	244,654	279,722
Selling, general and administrative expenses	(91,902)	(91,771)
Research and development expenses	(54,249)	(72,996)
Amortization of intangible assets associated with products	(3,209)	(3,476)
Other income	26,403	3,384
Other expenses	(4,257)	(4,551)
Operating profit	117,438	110,312
Finance income	26,522	16,797
Finance costs	(941)	(841)
Profit before tax	143,018	126,268
Income tax expense	(30,956)	(12,829)
Profit	112,061	113,439
Profit attributable to		
Owners of parent	111,858	114,185
Non-controlling interests	203	(746)
Profit	112,061	113,439
Earnings per share		(yen)
Basic earnings per share	365.03	378.75
Diluted earnings per share	364.89	378.63

Consolidated statement of comprehensive income

(Millions of yen)

	Year ended March 31, 2021	Year ended March 31, 2022
Profit	¥ 112,061	¥ 113,439
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	(4,677)	17,846
Remeasurements of defined benefit plans	(96)	(333)
Total of items that will not be reclassified to loss	(4,774)	17,513
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	36,049	29,793
Effective portion of cash flow hedges	(5,828)	1,023
Total of items that may be reclassified to profit or loss	30,221	30,817
Total other comprehensive (loss) income, net of tax	25,447	48,330
Comprehensive income	137,509	161,769
Comprehensive income attributable to		
Owners of parent	137,407	161,865
Non-controlling interests	101	(95)
Comprehensive income	137,509	161,769

Consolidated statement of changes in equity

(Millions of yen)

	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity	Equity attributable to owners of parent	Non-controlling interests	Total equity
Balance as of April 1, 2020	¥ 21,279	¥ 21,025	¥ (77,292)	¥ 708,291	¥ 91,848	¥ 765,152	¥ 51	¥ 765,203
Profit				111,858		111,858	203	112,061
Total other comprehensive income, net of tax					25,548	25,548	(101)	25,447
Comprehensive income	—	—	—	111,858	25,548	137,407	101	137,509
Purchase of treasury shares			(50,013)			(50,013)		(50,013)
Disposal of treasury shares		(4,705)	38,404			33,698		33,698
Cancellation of treasury shares		(30,912)	30,912			—		—
Dividends				(32,543)		(32,543)		(32,543)
Changes in scope of consolidation						—	10,696	10,696
Changes in ownership interest in subsidiaries		(7,593)				(7,593)	7,593	—
Transfer from other components of equity to retained earnings				71	(71)	—		—
Other		35,919		(35,430)	(488)	(0)		(0)
Balance as of March 31, 2021	21,279	13,733	(57,989)	752,248	116,836	846,108	18,442	864,550
Profit				114,185		114,185	(746)	113,439
Total other comprehensive income, net of tax					47,679	47,679	650	48,330
Comprehensive income	—	—	—	114,185	47,679	161,865	(95)	161,769
Purchase of treasury shares			(14)			(14)		(14)
Disposal of treasury shares		(5)	147			141		141
Dividends				(33,162)		(33,162)		(33,162)
Transfer from other components of equity to retained earnings				(308)	308	—		—
Other		727		(5)		722	(722)	—
Balance as of March 31, 2022	21,279	14,455	(57,857)	832,958	164,824	975,661	17,624	993,285

Consolidated Financial Statements

Consolidated statement of cash flows

(Millions of yen)

	Year ended March 31, 2021	Year ended March 31, 2022
Cash flows from operating activities		
Profit before tax	¥ 143,018	¥ 126,268
Depreciation and amortization	14,779	16,351
Impairment losses	825	141
Finance income and finance costs	(25,836)	(15,597)
Decrease (increase) in trade and other receivables	2,993	(43,417)
Decrease (increase) in inventories	(3,435)	(7,133)
Increase (decrease) in trade and other payables	(2,380)	11,686
Other	(16,524)	15,087
Subtotal	113,438	103,387
Interest and dividends received	28,111	24,807
Interest paid	(256)	(87)
Income taxes paid	(32,254)	(39,324)
Income taxes refund	—	13,286
Net cash provided by operating activities	109,039	102,068
Cash flows from investing activities		
Payments into time deposits	(230,468)	(260,380)
Proceeds from withdrawal of time deposits	269,696	234,685
Purchase of property, plant and equipment	(28,182)	(26,185)
Purchase of intangible assets	(4,762)	(5,379)
Payments for acquisition of subsidiaries	(3,636)	—
Purchase of investments	(120,478)	(139,396)
Proceeds from sale of investments	116,265	99,511
Other	(3,694)	940
Net cash used in investing activities	(5,261)	(96,204)
Cash flows from financing activities		
Repayments of lease liabilities	(3,648)	(3,453)
Purchase of treasury shares	(50,134)	(14)
Proceeds from sale of treasury shares	33,534	—
Dividends paid	(32,529)	(33,146)
Payments for acquisition of interests in subsidiaries from non-controlling interests	(1,575)	—
Capital contribution from non-controlling interests	10,464	—
Other	(0)	—
Net cash used in financing activities	(43,891)	(36,615)
Effect of exchange rate changes on cash and cash equivalents	7,425	8,998
Net increase (decrease) in cash and cash equivalents	67,312	(21,752)
Cash and cash equivalents at beginning of period	208,861	276,173
Cash and cash equivalents at end of period	¥ 276,173	¥ 254,420

Non-Financial Data

	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2022	Remarks	
Information on the number of employees (Information about only Shionogi & Co., Ltd. unless otherwise stated)	No. of employees						
	Consolidated	5,120 persons	5,233 persons (4,554 persons)	5,222 persons (4,527 persons)	5,485 persons (4,617 persons)	5,693 persons (4,507 persons)	The figures in parentheses are calculated for domestic consolidated companies.
	Shionogi & Co., Ltd.	3,677 persons	3,596 persons	2,667 persons	2,589 persons	2,510 persons	
	Rate of female employees	27.8%	28.1% (32.2%)	24.1% (32.2%)	25.4% (32.7%)	25.8% (33.8%)	The figures in parentheses are calculated for domestic consolidated companies.
	Average age						
	Total	41.4 years old	41.7 years old	41.3 years old	41.2 years old	41.6 years old	Excluding seconded persons
	Male	41.9 years old	42.2 years old	41.9 years old	41.8 years old	42.2 years old	
	Female	40.0 years old	40.4 years old	39.2 years old	39.3 years old	39.7 years old	
	Length of service						
	Total	17.3 years	17.3 years	15.9 years	15.7 years	16.0 years	Excluding seconded persons
	Male	16.9 years	17.1 years	16.1 years	16.0 years	16.3 years	
	Female	17.4 years	17.8 years	15.0 years	15.0 years	15.2 years	
	Average salary	9,193,748 yen	9,042,130 yen	9,431,304 yen	9,028,578 yen	8,574,848 yen	
	No. of new recruits						
	Total	110 persons	101 persons	94 persons	71 persons	63 persons	Recruits who will enter the company on April 1 of the following fiscal year
	Male	71 persons	59 persons	56 persons	37 persons	43 persons	
	Female	39 persons	42 persons	38 persons	34 persons	20 persons	
	Turnover rate of recruits enrolled for three years	6.5%	3.0%	4.5%	6.0%	4.5%	Recruits who entered the company on April 1 three years ago
	Turnover rate of employees	1.9%	1.6%	1.9%	1.9%	3.5%	Excluding retired persons
	No. of labor union members	2,758 persons	3,012 persons	2,806 persons	2,728 persons	2,606 persons	100% participation every year
	Employment rate of people with disabilities	2.2%	2.0% (2.5%)	2.0% (2.6%)	2.0% (2.7%)	1.8% (2.7%)	As of the end of March. The figures in parentheses are calculated for special cases in affiliated companies. Shionogi Smile Heart Co., Ltd. established in April 2018 and certified as a special subsidiary company in July 2018.
	No. of female managers	47 persons	40 persons (63 persons)	39 persons (68 persons)	37 persons (71 persons)	40 persons (74 persons)	As of April 1 of the following fiscal year. The figure in parentheses is calculated for domestic consolidated companies.
	Rate of female managers	8.0%	9.9% (10.0%)	10.7% (11.4%)	10.4% (11.5%)	11.4% (12.4%)	As of April 1 of the following fiscal year. The figures in parentheses are calculated for domestic consolidated companies. Target: 15% (Domestic consolidation at the end of March 2023)
Rate of female heads of organizations	7.7%	8.6%	14.3%	12.7%	12.3%	As of April 1 of the following fiscal year	
Rate of female corporate officers	1/14 7.1%	1/13 7.7%	0/10 0.0%	0/10 0.0%	0/10 0.0%	As of April 1 of the following fiscal year	
Rate of female members of the Board	16.7%	16.7%	16.7%	40.0%	40.0%	As of April 1 of the following fiscal year	
Information on labor management (Shionogi & Co., Ltd.)	Annual regular working hours for employees	1,860 hours	1,852 hours	1,845 hours	1,837 hours	1,762 hours	
	No. of paid holidays	Up to 24 days	Up to 24 days	Up to 21 days	Up to 21 days	Up to 21 days	The number of legal annual holidays based on the Labor Standards Act is up to 20 days.
	Average No. of paid holidays taken by employees	12.0 days	12.5 days	12.6 days	12.6 days	13.0 days	
	Acquisition rate of childcare leave						
	Female	100%	100%	100%	100%	100%	Rate of employees who have taken childcare leave during the year when their baby was born
	Male	21.0%	24.2%	32.8%	41.1%	51.4%	
	No. of employees who have taken nursing care leave						
	Female	4 persons	2 persons	4 persons	1 person	1 person	Total number
	Male	0 person	0 person	1 person	0 person	0 person	
	No. of employees who have worked on short work hours due to child rearing						
	Female	162 persons	119 persons	136 persons	130 persons	146 persons	Total number
	Male	1 person	1 person	1 person	1 person	2 persons	
	Volunteer leave	1 person	0 person	1 person	1 person	1 person	
	Leave for bone marrow transplant donors	0 person	0 person	1 person	1 person	0 person	
	Frequency rate	0.39	0.81	0.19	0.19	0.20	
	Severity rate	0.003	0.018	0.0002	0.0047	0.0049	
	Legal violations with serious fines or other sanctions	0 case	0 case	0 case	0 case	0 case	
Health (Domestic consolidated companies)	Smoking rate	16.4%	15.2%	14.2%	11.0%	7.1%	
	Rate of stress check attendance	94%	96%	95%	94%	94%	
	Participation rate in a healthy walk	42.2%	41.5%	41.5%	40.4%	31.4%	
	Rate of health checkup attendance	100%	100%	100%	100%	100%	
	Rate of employees on leave due to mental disorders	0.4%	0.4%	0.5%	0.6%	0.7%	
Environment (Information about domestic consolidated companies only unless otherwise stated)	GHG emissions (Scope 1 and 2)	90,136 tons-CO ₂	82,711 tons-CO ₂	82,209 tons-CO ₂	79,201 tons-CO ₂	84,164 tons-CO ₂	Note 1
	Total energy consumption	327,441MWh	314,174MWh	299,760MWh	305,339MWh	333,548MWh	Note 2
	Water use (Thousand)	1,389m ³	1,315m ³	1,263m ³	1,217m ³	1,366m ³	
	Amount of waste generated	3,486 tons	3,824 tons	3,062 tons	4,180 tons	5,169 tons	
	Recycling rate	78%	81%	83%	87%	89%	
	Landfill rate	1.0%	0.8%	1.0%	0.6%	0.9%	
	Hazardous waste	1,162 tons	1,830 tons	1,227 tons	1,722 tons	2,177 tons	
	Type 1 chemicals designated under the PRTR ACT						
	Amount handled	251 tons	274 tons	203 tons	257 tons	560 tons	
	Amount released	35 tons	43 tons	34 tons	94 tons	37 tons	
Amount transferred	177 tons	156 tons	131 tons	114 tons	498 tons		
No. of complaints about the environment	2 cases	1 case	0 case	0 case	3 cases		
Compliance (Domestic consolidated companies)	Number of disciplinary dismissals of employees due to violations of laws for the prevention of corruption and bribery*	—	0 case	0 case	0 case	0 case	*FCPA in the U.S., Bribery Act in the UK, Unfair Competition Prevention Act in Japan
	Costs related to fines, punishments, and settlements of violations of laws for the prevention of corruption and bribery*	—	0 yen	0 yen	0 yen	0 yen	
Other (Information about only Shionogi & Co., Ltd. unless otherwise stated)	Market capitalization	¥1,743.8 billion	¥2,170.5 billion	¥1,684.4 billion	¥1,854.6 billion	¥2,346.2 billion	
	Donations	¥1,020 million	¥949 million	¥1,065 million	¥1,069 million	¥817 million	
	Code of Conduct Rate of digital signature	—	—	—	100%	100%	Domestic consolidated companies
	Code of Conduct Rate of training participation	—	—	—	100%	100%	

Note 1: Including Nanjing Plant (Nanjing Chang'ao Pharmaceutical Co., Ltd.). Emissions from UMN Pharma, Inc. and Nagase Medicals Co., Ltd. (currently Shionogi Pharma Co., Ltd., Itami Plant), which constitute the boundary for SBT targets, included as of fiscal 2019.

Note 2: Including Nanjing Plant (Nanjing Chang'ao Pharmaceutical Co., Ltd.). Energy consumption by Nagase Medicals Co., Ltd. (currently Shionogi Pharma Co., Ltd., Itami Plant) included as of fiscal 2021.

Corporate Information/Stock Information

Corporate Data (As of March 31, 2022)

Company Name	Shionogi & Co., Ltd
Established	March 17, 1878
Incorporated	June 5, 1919
Paid-in Capital	¥21,279 million
Number of Employees	5,693 (Consolidated)
Fiscal Year-End	March 31
Website	https://www.shionogi.com/global/en/

Stock Information (As of March 31, 2022)


■ Stock (Securities) Listings:

Tokyo (#4507) (Shares listed in 1949)

■ Stock Status:

Common Stock Authorized: 1,000,000,000 shares
 Issued: 311,586,165 shares
 (Including 10,103,385 shares of treasury shares)
 Number of shareholders: 98,031

■ Shareholder Composition



Note: Treasury shares included in Individuals.

■ Major Shareholders

Name	Number of shares (Thousands)	Percentage of total shares (%)
The Master Trust Bank of Japan, Ltd. (Trust account)	63,344	21.01
Custody Bank of Japan, Ltd. (Trust account)	19,271	6.39
Sumitomo Life Insurance Company	18,604	6.17
SMBC Trust Bank Ltd. (as a trustee for retirement benefit of Sumitomo Mitsui Banking Corporation)	9,485	3.14
Nippon Life Insurance Company	8,409	2.78
JP MORGAN CHASE BANK 385632	7,582	2.51
BANK OF CHINA (HONG KONG) LIMITED-PING AN LIFE INSURANCE COMPANY OF CHINA, LIMITED	6,356	2.10
STATE STREET BANK WEST CLIENT - TREATY 505234	4,973	1.64
NORTHERN TRUST CO. (AVFC) SUB A/C AMERICAN CLIENTS	4,931	1.63
Sumitomo Mitsui Banking Corporation	4,595	1.52

Notes:

1. The Company owns 10,103,385 shares of treasury shares but the Company is not included in the major shareholders listed above (top 10).
2. The percentage of total is calculated as the proportion of shares to 301,482,780 shares of total issued stock (excluding 10,103,385 shares of treasury shares).

